📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations? (2020)

First Author: Bradbury A

Attributed to: Understanding synthetic lethality of ATR inhibitors with DDR dysregulation common in ovarian cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.pharmthera.2019.107450

PubMed Identifier: 31836456

Publication URI: http://europepmc.org/abstract/MED/31836456

Type: Journal Article/Review

Volume: 207

Parent Publication: Pharmacology & therapeutics

ISSN: 0163-7258